Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126692901 | 12669290 | 1 | I | 20160711 | 20160812 | 20160819 | 20160819 | EXP | GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-53188UK | BOEHRINGER INGELHEIM | 53.00 | YR | F | Y | 0.00000 | 20160819 | CN | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126692901 | 12669290 | 1 | PS | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | Respiratory (inhalation) | U | 21395 | 18 | UG | ||||||||
| 126692901 | 12669290 | 2 | SS | DUORESP SPIROMAX | BUDESONIDEFORMOTEROL | 1 | Respiratory (inhalation) | U | 0 | QID | |||||||||
| 126692901 | 12669290 | 3 | C | BRICANYL | TERBUTALINE SULFATE | 1 | Respiratory (inhalation) | 2 MG | 0 | .5 | MG | QID | |||||||
| 126692901 | 12669290 | 4 | C | CALCICHEW | CALCIUM CARBONATE | 1 | Oral | 0 | |||||||||||
| 126692901 | 12669290 | 5 | C | CANNABIDIOL | CANNABIDIOL | 1 | Unknown | 0 | |||||||||||
| 126692901 | 12669290 | 6 | C | CANNABIS | CANNABIS SATIVA SUBSP. INDICA TOP | 1 | Unknown | 0 | 2.5 | G | |||||||||
| 126692901 | 12669290 | 7 | C | COCAINE | COCAINE | 1 | Unknown | 0 | 2.5 | G | |||||||||
| 126692901 | 12669290 | 8 | C | COCODAMOL | ACETAMINOPHENCODEINE PHOSPHATE | 1 | Oral | 0 | |||||||||||
| 126692901 | 12669290 | 9 | C | FEXOFENADINE | FEXOFENADINEFEXOFENADINE HYDROCHLORIDE | 1 | Oral | 0 | 180 | MG | |||||||||
| 126692901 | 12669290 | 10 | C | MONTELUKAST | MONTELUKAST SODIUM | 1 | Oral | 0 | 10 | MG | |||||||||
| 126692901 | 12669290 | 11 | C | QUININE | QUININE | 1 | Oral | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126692901 | 12669290 | 1 | Emphysema |
| 126692901 | 12669290 | 2 | Chronic obstructive pulmonary disease |
| 126692901 | 12669290 | 3 | Asthma |
| 126692901 | 12669290 | 4 | Osteoporosis |
| 126692901 | 12669290 | 5 | Product used for unknown indication |
| 126692901 | 12669290 | 6 | Product used for unknown indication |
| 126692901 | 12669290 | 7 | Product used for unknown indication |
| 126692901 | 12669290 | 8 | Arthritis |
| 126692901 | 12669290 | 9 | Rhinitis |
| 126692901 | 12669290 | 10 | Asthma |
| 126692901 | 12669290 | 11 | Muscle spasms |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126692901 | 12669290 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126692901 | 12669290 | Balance disorder | |
| 126692901 | 12669290 | Cataract | |
| 126692901 | 12669290 | Dizziness | |
| 126692901 | 12669290 | Eye pain | |
| 126692901 | 12669290 | Halo vision | |
| 126692901 | 12669290 | Headache | |
| 126692901 | 12669290 | Vision blurred |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |